A Phase 2 interventional study of Ketamine Hydrochloride and Midazolam injection in Major Depressive Disorder and Healthy Controls, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.
Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 15th largest by enrollment, is one of 6 that started in 2022, is one of 22 in phase 2, and was the 64th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 25–65
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 13 · Phase 4 16
First in 2004; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 38 across the 89 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 89 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
24 studies in Depressive Disorder, Major by University of Texas Southwestern Medical Center: 1 open now, 2 under way, none of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 24 studies in Depressive Disorder, Major by University of Texas Southwestern Medical Center, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 22nd registered.
University of Texas Southwestern Medical Center’s Depressive Disorder, Major studies by the year they started, since 2000.
11 of the studies testing ketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT06788249University of PennsylvaniaPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | 2026-12-15 |
| NCT06480201Texas A&M UniversityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 89 studies testing ketamine in Depressive Disorder, Major, from their registry updates:
Among University of Texas Southwestern Medical Center’s 24 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The study is investigating dysfunctions in neurocircuitry in regards to irritability with healthy controls (HC) and individuals with Major Depressive Disorder (MDD) by performing MRIs. The MDD group will also be randomized to receive ketamine or midazolam to investigate changes post-treatment in neurocircuitry with regards to irritability.
The proposed study aims to 1 (Aim 1) identify dysfunctions in neurocircuitry that engender irritability, and (Aim 2) determine how changes in neurocircuit function related to change in irritability. We will accomplish Aim 1 with resting-state and frustrative nonreward (FNR) task-based fMRI data from n=30 HCs and n=60 subjects with MDD ((Fig 3). For Aim 2, we will randomize the MDD cohort (n=60; same as Aim 1) to 2 weeks of twice-weekly 40-minutes long intravenous infusion of either ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) in a double-blind parallel-arm fashion, and by repeating clinical assessments and fMRI scans after the last infusion. The central hypothesis of the proposed study is that striatum is a key hub in the neurocircuitry of irritability, and that treatment-related improvement in irritability is associated with normalization of these neurocircuit functioning.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.
Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.
Drug: Ketamine Hydrochloride
Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.
Drug: Midazolam injection
Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
Resting State Functional Connectivity.
Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). Correlation coefficient represents a Fisher Z-transformed coefficient.
Time frame: Baseline
Striatal Response to Frustrative Nonreward (FNR).
Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.
Time frame: Baseline
Treatment-related Change in Striatum-habenula Functional Connectivity.
Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). MDD participants only. Correlation coefficient represents a Fisher Z-transformed coefficient.
Time frame: Assessed at baseline and end of treatment. See outcome measure 1 for baseline visit reporting
Treatment-related Change in Striatal Response to FNR.
Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.
Time frame: Baseline, at 14 days. See outcome measure 2 for baseline timepoint data
Change in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam.
Symptoms of irritability will be measured Concise Associated Symptom Tracking scale (CAST-IRR) where possible scores range from 5-25 and higher scores indicate greater severity of irritability. Reported scores represent change in scale units from baseline.
Time frame: 14 days (end of treatment)
Change in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale
Possible scores range from 0 to 60 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
Time frame: 14 days (end of treatment)
Change in Symptoms of Depression Measured by QIDS Report
Possible scores range from 0 to 27 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
Time frame: 14 days (end of treatment)
Change in Symptoms of Anxious Arousal Measured by MAS Questionnaire
Possible scores range from 10-50 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
Time frame: 14 days (end of treatment)
Number of Participants That Met Criteria for Experiencing an Anger Attack on Massachusetts General Hospital Anger Attack Questionnaire (AAQ)
Anger attacks were assessed for using the Massachusetts General Hospital Anger Attack Questionnaire (AAQ), which asks about symptoms of anger attacks. If certain criteria on the AAQ are met, the individual is counted as having experienced an anger attack.
Time frame: Baseline, at 14 days
Change in Brief Psychiatric Rating Scale Positive Domain
The Brief Psychiatric Rating Scale (BPRS) is a clinician-administered assessment used to capture acute behavioral changes throughout treatment. We used only the 4 items assessing positive symptoms of psychosis such as conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content for this study. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 4-28, where higher scores indicate psychiatric symptoms. MDD participants only.
Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
Change in Clinician-Administered Dissociative Symptom Scale
The Clinician-Administered Dissociative States Scale (CADSS) was used before and after each infusion to assess the severity of dissociative symptoms associated with study drug administration. Possible scores range from 0-5 where higher scores indicate worse outcome/more severe symptoms. MDD participants only
Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
Number of Participants Reporting Symptoms From the Patient Rated Inventory of Side Effects (PRISE)
The Patient Rated Inventory of Side Effects (PRISE) is a clinician administered questionnaire used to qualify side effects by identifying and evaluating the tolerability of each symptom. Symptoms are grouped into domains by organ class. Numbers reported here reflect number of participants who reported at least one symptom in a given class over the total study duration, from baseline to study exit. Please note that many "other" side effects are symptoms of depression, and many were present at baseline since this was an MDD population. Here, we report the number of participants who endorsed symptoms from each organ class of symptoms.
Time frame: Pre-infusion, Immediately post-infusion, and 1 hour post infusion at each infusion visit (approximately every 3 days), and study exit (approximately 14 days)
| Milestone | Healthy Control | MDD - Midazolam | MDD - Ketamine |
|---|---|---|---|
| Started | 42 | 31 | 31 |
| Completed | 42 | 30 | 29 |
| Not completed | 0 | 1 | 2 |
Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). Correlation coefficient represents a Fisher Z-transformed coefficient.
| Fisher z correlation coefficient | Healthy Control | MDD - Ketamine | MDD - Midazolam |
|---|---|---|---|
| Striatal network 1 - Habenula functional connectivity | -0.002355 ± 0.09229 | 0.02525 ± 0.07618 | 0.04504 ± 0.09565 |
| Striatal network 2 - Habenula functional connectivity | -0.005570 ± 0.01205 | -0.0006422 ± 0.009798 | -0.003755 ± 0.008074 |
| Striatal network 3 - Habenula functional connectivity | -0.003135 ± 0.04240 | 0.007026 ± 0.04591 | 0.005655 ± 0.042714 |
| Striatal network 4 - Habenula functional connectivity | -0.002556 ± 0.008471 | 0.0003311 ± 0.008567 | -0.001633 ± 0.007936 |
| Striatal network 5 - Habenula functional connectivity | -0.0006443 ± 0.01734 | 0.002509 ± 0.01250 | 0.0008957 ± 0.01424 |
| Striatal network 6 - Habenula functional connectivity | 0.0002023 ± 0.007428 | 0.001734 ± 0.008458 | 0.0018644074 ± 0.007666 |
| Striatal network 7 - Habenula functional connectivity | 0.0005949 ± 0.008584 | 0.001678 ± 0.009290 | 0.0007463 ± 0.008234 |
Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.
| Estimated BOLD signal (beta estimate) | Healthy Control | MDD - Ketamine | MDD - Midazolam |
|---|---|---|---|
| Contrast of striatal network 1 activation following frustrating vs positive feedback | 0.008095 ± 0.1880 | 0.0299566552 ± 0.2375327599 | 0.0575584643 ± 0.2340562227 |
| Contrast of striatal network 2 activation following frustrating vs positive feedback | 0.02017 ± 0.1006 | -0.002985828 ± 0.1059210865 | 0.0429733571 ± 0.0997051875 |
| Contrast of striatal network 3 activation following frustrating vs positive feedback | -0.015433282 ± 0.1624008534 | -0.012460897 ± 0.1447045331 | 0.027166 ± 0.1874875272 |
| Contrast of striatal network 4 activation following frustrating vs positive feedback | 0.009815 ± 0.1041 | 0.0065397241 ± 0.1068566889 | 0.0501653214 ± 0.1030575279 |
| Contrast of striatal network 5 activation following frustrating vs positive feedback | 0.01036 ± 0.1346 | 0.0424085517 ± 0.1015805136 | 0.0648926429 ± 0.1293505982 |
| Contrast of striatal network 6 activation following frustrating vs positive feedback | 0.006723 ± 0.1402 | 0.0016498966 ± 0.1287143706 | 0.0320963929 ± 0.1118624523 |
| Contrast of striatal network 7 activation following frustrating vs positive feedback | 0.02340 ± 0.1237 | 0.03740475 ± 0.1128758572 | 0.03740475 ± 0.1110403024 |
Functional connectivity refers to the standardized correlation between resting state BOLD signal measured by fMRI of 7 striatal regions and habenula region of the brain (higher correlation means higher connectivity). Parcels from the striatal regions of the Schaefer atlas (2018) were assigned to the 7 resting state networks outlined by Yeo (2011) (i.e. Schaefer-Yeo atlas was used). MDD participants only. Correlation coefficient represents a Fisher Z-transformed coefficient.
| Fisher z correlation coefficient | MDD - Ketamine | MDD - Midazolam |
|---|---|---|
| Striatal network 1 - Habenula functional connectivity | -0.0009734 ± 0.05776 | -0.01185 ± 0.07534 |
| Striatal network 2 - Habenula functional connectivity | -0.002656739 ± 0.0160103506 | -0.000169 ± 0.0100583457 |
| Striatal network 3 - Habenula functional connectivity | -0.012500043 ± 0.037625987 | -0.000802696 ± 0.037625987 |
| Striatal network 4 - Habenula functional connectivity | -0.004466304 ± 0.0122943308 | 0.0017146522 ± 0.0091285944 |
| Striatal network 5 - Habenula functional connectivity | 0.003012087 ± 0.015576652 | 0.0029876957 ± 0.0126743798 |
| Striatal network 6 - Habenula functional connectivity | -0.001122 ± 0.0092733779 | 0.0013288696 ± 0.0109347196 |
| Striatal network 7 - Habenula functional connectivity | -0.001283609 ± 0.0121899456 | 0.0000793913 ± 0.0108864131 |
Difference between striatal response to frustrative nonreward (FNR) vs striatal response to positive feedback on the Affective Posner 3 task, as measured by the estimated difference in BOLD (Blood Oxygen Level Dependent) signal within the striatum regions of the brain (beta estimate from general linear test; from gltsym in AFNI's afniproc command). 7 regions correspond to those outlined by Schaefer-Yeo atlas 7-network version.
| Estimated BOLD signal (beta estimate) | MDD - Ketamine | MDD - Midazolam |
|---|---|---|
| Contrast of striatal network 1 activation following frustrating vs positive feedback | -0.043221536 ± 0.2355486241 | -0.049248448 ± 0.2134111013 |
| Contrast of striatal network 2 activation following frustrating vs positive feedback | 0.0277769643 ± 0.0785526745 | 0.0244194138 ± 0.093963263 |
| Contrast of striatal network 3 activation following frustrating vs positive feedback | 0.02633 ± 0.0982122041 | 0.0057957931 ± 0.1500521724 |
| Contrast of striatal network 4 activation following frustrating vs positive feedback | 0.034981931 ± 0.0916752534 | 0.03323825 ± 0.0902350144 |
| Contrast of striatal network 5 activation following frustrating vs positive feedback | 0.0333037857 ± 0.1005225603 | 0.0322243103 ± 0.1231102155 |
| Contrast of striatal network 6 activation following frustrating vs positive feedback | 0.0173799286 ± 0.0973618907 | 0.0228358276 ± 0.0953103359 |
| Contrast of striatal network 7 activation following frustrating vs positive feedback | 0.0299317857 ± 0.0685636315 | 0.0282071034 ± 0.0950889413 |
Symptoms of irritability will be measured Concise Associated Symptom Tracking scale (CAST-IRR) where possible scores range from 5-25 and higher scores indicate greater severity of irritability. Reported scores represent change in scale units from baseline.
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Change in Symptoms of Irritability After Two Weeks of Twice-weekly Infusions of Ketamine Versus Midazolam. | -4.87 ± 4.66 | -2.87 ± 3.91 |
Possible scores range from 0 to 60 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Change in Symptoms of Depression (Including Suicidal Ideation) Measured by MADR Scale | -13.84 ± 9.93 | -8.95 ± 9.94 |
Possible scores range from 0 to 27 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Change in Symptoms of Depression Measured by QIDS Report | -5.90 ± 4.28 | -3.39 ± 3.90 |
Possible scores range from 10-50 where higher scores indicate worse outcome. Reported scores represent change in scale units from baseline
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Change in Symptoms of Anxious Arousal Measured by MAS Questionnaire | -4.94 ± 5.56 | -3.10 ± 5.01 |
Anger attacks were assessed for using the Massachusetts General Hospital Anger Attack Questionnaire (AAQ), which asks about symptoms of anger attacks. If certain criteria on the AAQ are met, the individual is counted as having experienced an anger attack.
| Participants | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Baseline | 10 | 5 |
| Study exit (14 days) | 3 | 4 |
The Brief Psychiatric Rating Scale (BPRS) is a clinician-administered assessment used to capture acute behavioral changes throughout treatment. We used only the 4 items assessing positive symptoms of psychosis such as conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content for this study. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 4-28, where higher scores indicate psychiatric symptoms. MDD participants only.
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Pre-infusion: Infusion 1 | 4.08 ± 0.27 | 4.08 ± 0.27 |
| Immediate post-infusion: Infusion 1 | 4.11 ± 0.58 | 4.04 ± 0.20 |
| 1 hr post-infusion: Infusion 1 | 4.00 ± 0.00 | 4.00 ± 0.00 |
| Pre-infusion: Infusion 2 | 4.03 ± 0.19 | 4.08 ± 0.28 |
| Immediate post-infusion: Infusion 2 | 4.07 ± 0.37 | 4.08 ± 0.28 |
| 1 hr post-infusion: Infusion 2 | 4.00 ± 0.00 | 4.08 ± 0.28 |
| Pre-infusion: Infusion 3 | 4.00 ± 0.00 | 4.04 ± 0.20 |
| Immediate post-infusion: Infusion 3 | 4.00 ± 0.00 | 4.04 ± 0.20 |
| 1 hr post-infusion: Infusion 3 | 4.00 ± 0.00 | 4.04 ± 0.20 |
| Pre-infusion: Infusion 4 | 4.00 ± 0.00 | 4.08 ± 0.28 |
| Immediate post-infusion: Infusion 4 | 4.07 ± 0.38 | 4.08 ± 0.28 |
| 1 hr post-infusion: Infusion 4 | 4.00 ± 0.00 | 4.08 ± 0.28 |
| Study exit (No infusions on study exit, so only 1 timepoint here) | 4.03 ± 0.18 | 4.00 ± 0.00 |
The Clinician-Administered Dissociative States Scale (CADSS) was used before and after each infusion to assess the severity of dissociative symptoms associated with study drug administration. Possible scores range from 0-5 where higher scores indicate worse outcome/more severe symptoms. MDD participants only
| Score on a scale | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Infusion 1: Pre-infusion | 0.85 ± 2.07 | 0.77 ± 2.03 |
| Infusion 1: Immediate post-infusion | 12.15 ± 11.18 | 0.92 ± 1.79 |
| Infusion 1: 1 hr post-infusion | 0.44 ± 1.40 | 0.11 ± 0.43 |
| Infusion 2: Pre-infusion | 0.24 ± 0.64 | 0.40 ± 0.96 |
| Infusion 2: Immediate post-infusion | 12.34 ± 16.16 | 1.12 ± 2.09 |
| Infusion 2: 1 hr post-infusion | 0.34 ± 0.90 | 0.04 ± 0.20 |
| Infusion 3: Pre-infusion | 0.14 ± 0.58 | 0.24 ± 0.83 |
| Infusion 3: Immediate post-infusion | 10.48 ± 13.33 | 0.46 ± 0.83 |
| Infusion 3: 1 hr post-infusion | 0.10 ± 0.31 | 0.08 ± 0.28 |
| Infusion 4: Pre-infusion | 0.15 ± 0.44 | 0.17 ± 0.56 |
| Infusion 4: Immediate post-infusion | 9.96 ± 17.61 | 0.79 ± 1.74 |
| Infusion 4: 1 hr post-infusion | 0.04 ± 0.19 | 0.08 ± 0.28 |
| Study exit (No infusions on study exit, so only 1 timepoint here) | 0.29 ± 0.82 | 0.19 ± 0.65 |
The Patient Rated Inventory of Side Effects (PRISE) is a clinician administered questionnaire used to qualify side effects by identifying and evaluating the tolerability of each symptom. Symptoms are grouped into domains by organ class. Numbers reported here reflect number of participants who reported at least one symptom in a given class over the total study duration, from baseline to study exit. Please note that many "other" side effects are symptoms of depression, and many were present at baseline since this was an MDD population. Here, we report the number of participants who endorsed symptoms from each organ class of symptoms.
| Participants | MDD: Ketamine | MDD: Midazolam |
|---|---|---|
| Number of participants who reported gastrointestinal symptoms | 23 | 21 |
| Number of participants who reported heart-related symptoms | 12 | 9 |
| Number of participants who reported skin related symptoms | 14 | 5 |
| Number of participants who reported nervous system related symptoms | 27 | 21 |
| Number of participants who reported eye/ear related symptoms | 25 | 11 |
| Number of participants who reported genital/urinary related symptoms | 5 | 3 |
| Number of participants who reported sleep-related symptoms | 24 | 27 |
| Number of participants who reported sexual functioning-related symptoms | 13 | 15 |
| Number of participants who reported other symptoms | 30 | 30 |
| Number of participants reporting distressing gastrointestinal symptoms | 5 | 2 |
| Number of participants reporting distressing heart-related symptoms | 2 | 3 |
| Number of participants reporting distressing skin-related symptoms | 2 | 0 |
| Number of participants reporting distressing nervous system-related symptoms | 5 | 3 |
| Number of participants reporting distressing eye/ear related symptoms | 3 | 1 |
| Number of participants reporting distressing genital/urinary-related symptoms | 1 | 1 |
| Number of participants reporting distressing sleep-related symptoms | 9 | 12 |
| Number of participants reporting distressing sexual functioning-related symptoms | 4 | 6 |
| Number of participants reporting other distressing symptom(s) | 16 | 15 |
Collected over From date of informed consent until end of follow-up (maximum of 5 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDD: Ketamine | 0/31 (0%) | 0/31 (0%) | 11/31 (35.5%) |
| MDD: Midazolam | 0/31 (0%) | 0/31 (0%) | 5/31 (16.1%) |
| Healthy Control | 0/42 (0%) | 0/42 (0%) | 1/42 (2.4%) |
| Event | MDD: Ketamine | MDD: Midazolam | Healthy Control |
|---|---|---|---|
| NauseaGastrointestinal disorders | 10/31 | 1/31 | 1/42 |
| HeadacheNervous system disorders | 4/31 | 4/31 | 0/42 |
MDD participants were randomized to receive either ketamine or midalozam infusions
| Age, Continuous(Years) | Healthy Controls | MDD - Ketamine | MDD - Midazolam | Total |
|---|---|---|---|---|
| Mean | 39.9 ± 14.1 | 38.0 ± 12.5 | 43.0 ± 14.6 | 40.3 ± 13.8 |
| Sex: Female, Male(Participants) | Healthy Controls | MDD - Ketamine | MDD - Midazolam | Total |
|---|---|---|---|---|
| Female | 23 | 25 | 12 | 60 |
| Male | 19 | 6 | 19 | 44 |
| Race (NIH/OMB)(Participants) | Healthy Controls | MDD - Ketamine | MDD - Midazolam | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 3 | 4 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 2 | 4 | 8 |
| White | 26 | 21 | 22 | 69 |
| More than one race | 0 | 4 | 1 | 5 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Controls | MDD - Ketamine | MDD - Midazolam | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 1 | 10 |
| Not Hispanic or Latino | 37 | 27 | 29 | 93 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — IPD will be shared based on institutional approval
Ran from May 2022 to primary completion in Apr 2025, 35 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's 35 months is close to that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
University of Texas Southwestern Medical Center →